WALTHAM, Mass.--(BUSINESS WIRE)--Aug 29, 2018--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:

H.C. Wainwright 20th Annual Global Investment Conference Date: Wednesday, September 5 Presentation Time: 3:00 p.m. ET Location: New York, NY

2018 Wells Fargo Healthcare Conference Date: Thursday, September 6 Presentation Time: 11:30 a.m. ET Location: Boston, MA

Morgan Stanley 16th Annual Global Healthcare Conference Date: Wednesday, September 12 Fireside Chat Time: 5:25 p.m. ET Location: New York, NY

To access a live webcast and subsequent archived recording of the presentations, please visit the “Investors & Media” section on the Kala website at http://kalarx.com/.

About Kala

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary Mucus Penetrating Particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid, LE, designed for ocular applications, resulting in the recent approval of INVELTYS for the treatment of inflammation and pain following ocular surgery. Kala plans to submit a New Drug Application for KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease in the second half of 2018.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180829005705/en/

CONTACT: For Kala Pharmaceuticals, Inc.

Investors

Michael Schaffzin, 212-362-1200

michael@sternir.com

or

Media

Kari Watson, 781-235-3060

kwatson@macbiocom.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES OPTICAL PHARMACEUTICAL

SOURCE: Kala Pharmaceuticals, Inc.

Copyright Business Wire 2018.

PUB: 08/29/2018 04:01 PM/DISC: 08/29/2018 04:01 PM

http://www.businesswire.com/news/home/20180829005705/en